Piper Sandler analyst Edward Tenthoff initiated coverage of Inovio (INO) with an Overweight rating and $5 price target The company is is developing DNA-encoded medicines to treat cancer, infectious and rare diseases, the analyst tells investors in a research note. The firm says INO-3107, being developed to treat recurrent respiratory papillomatosis caused by human papillomavirus, was well tolerated and achieved robust clinical efficacy in a Phase I/II study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INO:
- Inovio Pharmaceuticals Announces Public Offering Agreement
- Inovio Pharmaceuticals’ Glioblastoma Study Update: What Investors Need to Know
- Inovio 14.286M share Spot Secondary priced at $1.75
- Inovio announces common stock and warrants offering, no amount given
- Inovio Pharmaceuticals Holds Annual Stockholders Meeting